Monthly
US$200
Billed every month
瑞舒伐他汀钙片
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 5 applicationsSupplement delivery: 3 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders35View records ↓
Under-review filings18View records ↓
This year’s generic filers6View records ↓
NHSA approval numbers64View records ↓
API companies with A status31View records ↓
Chemical-drug catalogue
Loaded records: 35 holders; 6 in the quality-and-efficacy consistency-evaluation category, and 28 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 翎耀生物科技（上海）有限公司 | 江苏复旦复华药业有限公司 | 国药准字H20263143 | 2026/01/20 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 瑞阳制药股份有限公司 | 瑞阳制药股份有限公司 | 国药准字H20269013 | 2026/01/19 | 5mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20255893 | 2025/11/12 | 5mg（按C22H28FN3O6S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20255892 | 2025/11/12 | 10mg（按C22H28FN3O6S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州东瑞制药有限公司 | 苏州东瑞制药有限公司 | 国药准字H20247200 | 2024/09/02 | 10mg（按 C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都恒瑞制药有限公司 | 成都恒瑞制药有限公司 | 国药准字H20244465 | 2024/07/16 | 10mg（按C<sub>22</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>6</sub>S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西兰花药业股份有限公司 | 山西兰花药业股份有限公司 | 国药准字H20237182 | 2023/12/25 | 5mg(按C<sub>22</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>6</sub>S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州东瑞制药有限公司 | 苏州东瑞制药有限公司 | 国药准字H20234598 | 2023/12/05 | 20mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林天衡药业有限公司 | 北京天衡药物研究院南阳天衡制药厂 | 国药准字H20234183 | 2023/09/19 | 5mg（以C<sub>22</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>6</sub>S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林天衡药业有限公司 | 北京天衡药物研究院南阳天衡制药厂 | 国药准字H20234184 | 2023/09/19 | 10mg（按C<sub>22</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>6</sub>S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 乐普制药科技有限公司 | 乐普制药科技有限公司 | 国药准字H20233778 | 2023/06/27 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云鹏医药集团有限公司 | 云鹏医药集团有限公司 | 国药准字H20233536 | 2023/05/12 | 10mg（以C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天地恒一制药股份有限公司 | 天地恒一制药股份有限公司 | 国药准字H20233495 | 2023/04/17 | 5mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天地恒一制药股份有限公司 | 天地恒一制药股份有限公司 | 国药准字H20233494 | 2023/04/17 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏悦兴药业有限公司 | 江苏悦兴药业有限公司 | 国药准字H20223483 | 2022/07/07 | 10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20227079 | 2022/06/09 | 5mg(按瑞舒伐他汀计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天方药业有限公司 | 天方药业有限公司 | 国药准字H20223159 | 2022/03/22 | 5mg（以C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 瑞阳制药股份有限公司 | 瑞阳制药股份有限公司 | 国药准字H20223163 | 2022/03/22 | 10mg（以C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天方药业有限公司 | 天方药业有限公司 | 国药准字H20223160 | 2022/03/22 | 10mg（以C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药股份有限公司 | 山东鲁抗医药股份有限公司 | 国药准字H20213943 | 2021/12/14 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波科尔康美诺华药业有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20213616 | 2021/07/28 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波科尔康美诺华药业有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20213615 | 2021/07/28 | 5mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波科尔康美诺华药业有限公司 | 宁波科尔康美诺华药业有限公司 | 国药准字H20213617 | 2021/07/28 | 20mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南九典制药股份有限公司 | 湖南九典制药股份有限公司 | 国药准字H20213588 | 2021/07/20 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海上药信谊药厂有限公司 | 上海上药信谊药厂有限公司 | 国药准字H20213421 | 2021/05/26 | 5mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海上药信谊药厂有限公司 | 上海上药信谊药厂有限公司 | 国药准字H20213422 | 2021/05/26 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西兰花药业股份有限公司 | 山西兰花药业股份有限公司 | 国药准字H20213121 | 2021/02/02 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建东瑞制药有限公司 | 福建东瑞制药有限公司 | 国药准字H20213006 | 2021/01/05 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东东阳光药业有限公司 | 广东东阳光药业有限公司 | 国药准字H20203657 | 2020/12/08 | 按C22H28FN3O6S计5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东东阳光药业有限公司 | 广东东阳光药业有限公司 | 国药准字H20203658 | 2020/12/08 | 按C22H28FN3O6S计10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 青岛黄海制药有限责任公司 | 青岛黄海制药有限责任公司 | 国药准字H20203569 | 2020/11/10 | 瑞舒伐他汀（按C22H28FN3O6S计）20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 青岛黄海制药有限责任公司 | 青岛黄海制药有限责任公司 | 国药准字H20203568 | 2020/11/10 | 按瑞舒伐他汀（C22H28FN3O6S）计10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏万高药业股份有限公司 | 江苏万高药业股份有限公司 | 国药准字H20203501 | 2020/09/25 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 常州制药厂有限公司 | 常州制药厂有限公司 | 国药准字H20203480 | 2020/09/08 | 20mg(按C22H28FN3O6S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 常州制药厂有限公司 | 常州制药厂有限公司 | 国药准字H20203479 | 2020/09/08 | 10mg(按C22H28FN3O6S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 常州制药厂有限公司 | 常州制药厂有限公司 | 国药准字H20203478 | 2020/09/08 | 5mg(按C22H28FN3O6S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 赤峰赛林泰药业有限公司 | 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 2020/09/08 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江江北药业有限公司 | 浙江江北药业有限公司 | 国药准字H20203464 | 2020/09/02 | 10mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江江北药业有限公司 | 浙江江北药业有限公司 | 国药准字H20203463 | 2020/09/02 | 5mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20203427 | 2020/08/17 | 10mg(按瑞舒伐他汀计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20080669 | 2020/08/10 | 5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 合肥合源药业有限公司 | 合肥合源药业有限公司 | 国药准字H20203395 | 2020/08/05 | 5mg（按瑞舒伐他汀计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥合源药业有限公司 | 合肥合源药业有限公司 | 国药准字H20203396 | 2020/08/05 | 10mg（按瑞舒伐他汀计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏美罗药业有限公司 | 阿斯利康药业（中国）有限公司 | 国药准字H20203224 | 2020/05/26 | 10mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏美罗药业有限公司 | 阿斯利康药业（中国）有限公司 | 国药准字H20203223 | 2020/05/26 | 5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20203080 | 2020/03/03 | 5mg（按C22H28FN3O6S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥英太制药有限公司 | 合肥英太制药有限公司 | 国药准字H20203049 | 2020/02/20 | 10mg(按C22H28FN3O6S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Lek Pharmaceuticals d.d. | Lek Pharmaceuticals d.d. | H20180007 | 2019/04/03 | 5mg(以瑞舒伐他汀计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| Lek Pharmaceuticals d.d. | Lek Pharmaceuticals d.d. | H20180008 | 2019/04/03 | 10mg(以瑞舒伐他汀计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| — | 南京先声东元制药有限公司 | 国药准字H20113265 | 2019/03/05 | 5mg（按瑞舒伐他汀计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 鲁南贝特制药有限公司 | 鲁南贝特制药有限公司 | 国药准字H20080241 | 2019/02/02 | 10mg(按C22H28FN3O6S计) | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 鲁南贝特制药有限公司 | 鲁南贝特制药有限公司 | 国药准字H20080240 | 2019/02/02 | 5mg (按C22H28FN3O6S计) | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 海正辉瑞制药有限公司 | 浙江海正药业股份有限公司 | 国药准字H20143338 | — | 10mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 海正辉瑞制药有限公司 | 浙江海正药业股份有限公司 | 国药准字H20143337 | — | 5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| — | 南京先声东元制药有限公司 | 国药准字H20113246 | 2018/10/08 | 10mg（按瑞舒伐他汀计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| — | 浙江京新药业股份有限公司 | 国药准字H20080483 | 2018/02/09 | 10mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| — | 浙江京新药业股份有限公司 | 国药准字H20080482 | 2018/02/09 | 5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20080670 | 2017/12/27 | 10mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| Astrazeneca UK Limited | IPR Pharmaceuticals,INCORPORATED | H20160546 | 2006/12/27 | 5mg | Imported originator drug (进口原研药品) | CDE |
| Astrazeneca UK Limited | IPR Pharmaceuticals,INCORPORATED | H20160545 | 2006/12/27 | 10mg | Imported originator drug (进口原研药品) | CDE |
| Astrazeneca UK Limited | IPR Pharmaceuticals,INCORPORATED | H20160611 | 2006/12/27 | 20mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 64 distinct approval numbers and 37 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010100177 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20255892 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010101066 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203478 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010101397 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010101503 | NHSA |
| 先声药业有限公司 | 国药准字H20113246 | 10mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001010101594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001010101606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010101631 | NHSA |
| 苏州东瑞制药有限公司 | 国药准字H20234598 | 20mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010101650 | NHSA |
| 成都恒瑞制药有限公司 | 国药准字H20244465 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010102031 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010102763 | NHSA |
| 山西兰花药业股份有限公司 | 国药准字H20213121 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010102909 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010102968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010103006 | NHSA |
| 天方药业有限公司 | 国药准字H20223159 | 5mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010103098 | NHSA |
| 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010103865 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080241 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010104010 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20203568 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010104043 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010104152 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213615 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010104565 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143338 | 10mg | Category B (乙) | XC10AAR069A001010104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001010104658 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20213006 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010104876 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010104942 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20203657 | 按C22H28FN3O6S计5mg | Category B (乙) | XC10AAR069A001010106988 | NHSA |
| 安徽杰玺医药有限公司 | 国药准字H20203395 | 5mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010109541 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20234321 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010109563 | NHSA |
| Lek Pharmaceuticals d.d. | 国药准字J20190009 | 10mg(以瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010109659 | NHSA |
| Astrazeneca UK limited | 国药准字HJ20160546 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010178241 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010179303 | NHSA |
| Lek Pharmaceuticals d.d. | 国药准字HJ20180008 | 10mg(按C22H27FN3O6S计) | Category B (乙) | XC10AAR069A001010179428 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20233494 | 10mg( 按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010180086 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010180698 | NHSA |
| 上海上药信谊药厂有限公司 | 国药准字H20213421 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010181288 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20233778 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010182919 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20213943 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010183198 | NHSA |
| 翎耀生物科技(上海)有限公司 | 国药准字H20263143 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010183356 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010200177 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203478 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010201397 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010201503 | NHSA |
| 先声药业有限公司 | 国药准字H20113246 | 10mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001010201594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001010201606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010201631 | NHSA |
| 苏州东瑞制药有限公司 | 国药准字H20234598 | 20mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010201650 | NHSA |
| 成都恒瑞制药有限公司 | 国药准字H20244465 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010202031 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010202763 | NHSA |
| 山西兰花药业股份有限公司 | 国药准字H20213121 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010202909 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010202968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010203006 | NHSA |
| 天方药业有限公司 | 国药准字H20223159 | 5mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010203098 | NHSA |
| 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010203865 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080241 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010204010 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20203568 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010204043 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010204152 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213615 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010204565 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143338 | 10mg | Category B (乙) | XC10AAR069A001010204641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001010204658 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20213006 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010204876 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010204942 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20203658 | 按C22H28FN3O6S计10mg | Category B (乙) | XC10AAR069A001010206988 | NHSA |
| 安徽杰玺医药有限公司 | 国药准字H20203395 | 5mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010209541 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20234321 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010209563 | NHSA |
| Lek Pharmaceuticals d.d. | 国药准字J20190009 | 10mg(以瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010209659 | NHSA |
| Astrazeneca UK limited | 国药准字HJ20160546 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010278241 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010279303 | NHSA |
| Lek Pharmaceuticals d.d. | 国药准字HJ20180008 | 10mg(按C22H27FN3O6S计) | Category B (乙) | XC10AAR069A001010279428 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010280698 | NHSA |
| 上海上药信谊药厂有限公司 | 国药准字H20213421 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010281288 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20233778 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010282919 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20213943 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010283198 | NHSA |
| 翎耀生物科技(上海)有限公司 | 国药准字H20263143 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010283356 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010300177 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203478 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010301397 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010301503 | NHSA |
| 先声药业有限公司 | 国药准字H20113246 | 10mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001010301594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001010301606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010301631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010302763 | NHSA |
| 山西兰花药业股份有限公司 | 国药准字H20213121 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010302909 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010302968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010303006 | NHSA |
| 天方药业有限公司 | 国药准字H20223159 | 5mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010303098 | NHSA |
| 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010303865 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080241 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010304010 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213615 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010304565 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143338 | 10mg | Category B (乙) | XC10AAR069A001010304641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001010304658 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20213006 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010304876 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010304942 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20203658 | 按C22H28FN3O6S计10mg | Category B (乙) | XC10AAR069A001010306988 | NHSA |
| 安徽杰玺医药有限公司 | 国药准字H20203395 | 5mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010309541 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20234321 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010309563 | NHSA |
| Lek Pharmaceuticals d.d. | 国药准字J20190009 | 10mg(以瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010309659 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010379303 | NHSA |
| Lek Pharmaceuticals d.d. | 国药准字HJ20180008 | 10mg(按C22H27FN3O6S计) | Category B (乙) | XC10AAR069A001010379428 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010380698 | NHSA |
| 上海上药信谊药厂有限公司 | 国药准字H20213421 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010381288 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20233778 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010382919 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20213943 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010383198 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010400177 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203478 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010401397 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010401503 | NHSA |
| 先声药业有限公司 | 国药准字H20113246 | 10mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001010401594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001010401606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010401631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010402763 | NHSA |
| 山西兰花药业股份有限公司 | 国药准字H20213121 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010402909 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010402968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010403006 | NHSA |
| 天方药业有限公司 | 国药准字H20223159 | 5mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010403098 | NHSA |
| 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010403865 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080241 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010404010 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213615 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010404565 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143338 | 10mg | Category B (乙) | XC10AAR069A001010404641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001010404658 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20213006 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010404876 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010404942 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20203658 | 按C22H28FN3O6S计10mg | Category B (乙) | XC10AAR069A001010406988 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20234321 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010409563 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010479303 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010480698 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20233778 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010482919 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010500177 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203478 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010501397 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010501503 | NHSA |
| 先声药业有限公司 | 国药准字H20113246 | 10mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001010501594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001010501606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010501631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010502763 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010502968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010503006 | NHSA |
| 天方药业有限公司 | 国药准字H20223159 | 5mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010503098 | NHSA |
| 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010503865 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001010504658 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20213006 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010504876 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010504942 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20234321 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010509563 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010579303 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010580698 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20233778 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010582919 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010600177 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010601503 | NHSA |
| 先声药业有限公司 | 国药准字H20113246 | 10mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001010601594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001010601606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010601631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010602763 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010602968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010603006 | NHSA |
| 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010603865 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001010604658 | NHSA |
| 福建东瑞制药有限公司 | 国药准字H20213006 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010604876 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010604942 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010679303 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010680698 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20233778 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010682919 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010700177 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010701503 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010701631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010702763 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010702968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010703006 | NHSA |
| 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010703865 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001010704658 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010704942 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010779303 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010780698 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20233778 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010782919 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010800177 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010801503 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001010801606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010801631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010802763 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010802968 | NHSA |
| 赤峰赛林泰药业有限公司 | 国药准字H20203475 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010803865 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001010804658 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010804942 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010879303 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010880698 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20233778 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010882919 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20203080 | 5mg(按C22H28FN3O6S)计 | Category B (乙) | XC10AAR069A001010900177 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010901503 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001010901606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010901631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001010902763 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001010904942 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203463 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001010979303 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001010980698 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011001503 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011001631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001011002763 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001011004942 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011080698 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011101503 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011101631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001011102763 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001011104942 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011180698 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20203501 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011201503 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011201631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001011202763 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001011204942 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011280698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011301631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001011302763 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011380698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011401631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001011402763 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011480698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011501631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001011502763 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011580698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011601631 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203427 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001011602763 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011680698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011701631 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011780698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011801631 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011880698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001011901631 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001011980698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012001631 | NHSA |
| 合肥英太制药有限公司 | 国药准字H20203049 | 10mg(按C₂₂H₂₈FN₃O₆S计)) | Category B (乙) | XC10AAR069A001012080698 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012101631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012201631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012301631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012401631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012501631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012601631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012701631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012801631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001012901631 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20223483 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001013001631 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20255893 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020101066 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203479 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020101397 | NHSA |
| 先声药业有限公司 | 国药准字H20113265 | 5mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001020101594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080669 | 按瑞舒伐他汀(C22H28FN306S)计5mg | Category B (乙) | XC10AAR069A001020101606 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20247200 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020101650 | NHSA |
| 石家庄四药有限公司 | 国药准字H20227079 | 5mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001020102763 | NHSA |
| 山西兰花药业股份有限公司 | 国药准字H20237182 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020102909 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020102968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234183 | 5mg(以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020103006 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020103098 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080242 | 20mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001020104010 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20203568 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020104043 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020104152 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213616 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020104565 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20143339 | 20mg | Category B (乙) | XC10AAR069A001020104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20143284 | 20mg 按瑞舒伐他汀(C22H27FN306S)计 | Category B (乙) | XC10AAR069A001020104658 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020104942 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20203657 | 按C22H28FN3O6S计5mg | Category B (乙) | XC10AAR069A001020106988 | NHSA |
| 安徽杰玺医药有限公司 | 国药准字H20203396 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001020109541 | NHSA |
| Astrazeneca UK limited | 国药准字J20170007 | 20mg | Category B (乙) | XC10AAR069A001020110153 | NHSA |
| Astrazeneca UK limited | 国药准字HJ20160545 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020178241 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020179303 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20233495 | 5mg( 按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020180086 | NHSA |
| 上海上药信谊药厂有限公司 | 国药准字H20213422 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020181288 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203479 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020201397 | NHSA |
| 先声药业有限公司 | 国药准字H20113265 | 5mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001020201594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080669 | 按瑞舒伐他汀(C22H28FN306S)计5mg | Category B (乙) | XC10AAR069A001020201606 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20247200 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020201650 | NHSA |
| 石家庄四药有限公司 | 国药准字H20227079 | 5mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001020202763 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20233536 | 10mg( 以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020202968 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234183 | 5mg(以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020203006 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020203098 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20203568 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020204043 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020204152 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213616 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020204565 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20143339 | 20mg | Category B (乙) | XC10AAR069A001020204641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20143284 | 20mg 按瑞舒伐他汀(C22H27FN306S)计 | Category B (乙) | XC10AAR069A001020204658 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20203657 | 按C22H28FN3O6S计5mg | Category B (乙) | XC10AAR069A001020206988 | NHSA |
| 安徽杰玺医药有限公司 | 国药准字H20203396 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001020209541 | NHSA |
| Astrazeneca UK limited | 国药准字J20170007 | 20mg | Category B (乙) | XC10AAR069A001020210153 | NHSA |
| Astrazeneca UK limited | 国药准字HJ20160545 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020278241 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020279303 | NHSA |
| 上海上药信谊药厂有限公司 | 国药准字H20213422 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020281288 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203479 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020301397 | NHSA |
| 先声药业有限公司 | 国药准字H20113265 | 5mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001020301594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080669 | 按瑞舒伐他汀(C22H28FN306S)计5mg | Category B (乙) | XC10AAR069A001020301606 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20247200 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020301650 | NHSA |
| 石家庄四药有限公司 | 国药准字H20227079 | 5mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001020302763 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234183 | 5mg(以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020303006 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020303098 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213616 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020304565 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20143339 | 20mg | Category B (乙) | XC10AAR069A001020304641 | NHSA |
| 安徽杰玺医药有限公司 | 国药准字H20203396 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001020309541 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020379303 | NHSA |
| 上海上药信谊药厂有限公司 | 国药准字H20213422 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020381288 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203479 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020401397 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20247200 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020401650 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234183 | 5mg(以C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020403006 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020403098 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213616 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001020404565 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20143339 | 20mg | Category B (乙) | XC10AAR069A001020404641 | NHSA |
| 安徽杰玺医药有限公司 | 国药准字H20203396 | 10mg(按瑞舒伐他汀计) | Category B (乙) | XC10AAR069A001020409541 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020479303 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203479 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020501397 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020503098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020579303 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203479 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020601397 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020603098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020679303 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020703098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020779303 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020803098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020879303 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020903098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001020979303 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021003098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021079303 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021103098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021179303 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021203098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021279303 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021303098 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021379303 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021403098 | NHSA |
| 天方药业有限公司 | 国药准字H20223160 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001021503098 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203480 | 20mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030101397 | NHSA |
| 先声药业有限公司 | 国药准字H20113246 | 10mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001030101594 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001030101606 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030103006 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080240 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030104010 | NHSA |
| 青岛黄海制药有限责任公司 | 国药准字H20203568 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030104043 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030104152 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213617 | 20mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030104565 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143337 | 5mg | Category B (乙) | XC10AAR069A001030104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001030104658 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030104942 | NHSA |
| Astrazeneca UK limited | 国药准字J20170009 | 5mg | Category B (乙) | XC10AAR069A001030110153 | NHSA |
| Astrazeneca UK limited | 国药准字HJ20160611 | 20mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030178241 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030179303 | NHSA |
| 天地恒一制药股份有限公司 | 国药准字H20233494 | 10mg( 按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030180086 | NHSA |
| 常州制药厂有限公司 | 国药准字H20203480 | 20mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030201397 | NHSA |
| 先声药业有限公司 | 国药准字H20113246 | 10mg(按瑞舒伐他汀(C₂₂H₂₈FN₃O₆S)计) | Category B (乙) | XC10AAR069A001030201594 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080240 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030204010 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030204152 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213617 | 20mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030204565 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143337 | 5mg | Category B (乙) | XC10AAR069A001030204641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001030204658 | NHSA |
| Astrazeneca UK limited | 国药准字J20170009 | 5mg | Category B (乙) | XC10AAR069A001030210153 | NHSA |
| Astrazeneca UK limited | 国药准字HJ20160611 | 20mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030278241 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030279303 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080240 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030304010 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030304152 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213617 | 20mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030304565 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143337 | 5mg | Category B (乙) | XC10AAR069A001030304641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001030304658 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030379303 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080240 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030404010 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030404152 | NHSA |
| 宁波科尔康美诺华药业有限公司 | 国药准字H20213617 | 20mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001030404565 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143337 | 5mg | Category B (乙) | XC10AAR069A001030404641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001030404658 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030479303 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030504152 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001030504658 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030604152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030704152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030804152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001030904152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001031004152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001031104152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20223163 | 10mg(以C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001031204152 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001031304942 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001031404942 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001031479303 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001031504942 | NHSA |
| 浙江江北药业有限公司 | 国药准字H20203464 | 10mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001031579303 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001031604942 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001031704942 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001031804942 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20213588 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001031904942 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080669 | 按瑞舒伐他汀(C22H28FN306S)计5mg | Category B (乙) | XC10AAR069A001040101606 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001040103006 | NHSA |
| 鲁南贝特制药有限公司 | 国药准字H20080240 | 5mg(按C22H28FN3O6S计) | Category B (乙) | XC10AAR069A001040104010 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20269013 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001040104152 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143338 | 10mg | Category B (乙) | XC10AAR069A001040104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001040104658 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20269013 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001040204152 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001040204658 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20269013 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001040304152 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001040304658 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20269013 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001040404152 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001040404658 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20269013 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001040504152 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080482 | 5mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001040504658 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20269013 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001040604152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20269013 | 5mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001040704152 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20080670 | 按瑞舒伐他汀(C22H28FN306S)计10mg | Category B (乙) | XC10AAR069A001050101606 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001050103006 | NHSA |
| 瀚晖制药有限公司 | 国药准字H20143337 | 5mg | Category B (乙) | XC10AAR069A001050104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001050104658 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001050204658 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001050304658 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001060103006 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001060104658 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001060204658 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001060304658 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20080483 | 10mg(按C22H28FN306S计) | Category B (乙) | XC10AAR069A001060404658 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001070103006 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001080103006 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001090103006 | NHSA |
| 吉林天衡药业有限公司 | 国药准字H20234184 | 10mg(按C₂₂H₂₈FN₃O₆S计) | Category B (乙) | XC10AAR069A001100103006 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 18 filings and 9 distinct first applicants.
Generic 15 · Supplement 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江诺得药业有限公司 | CYHS2600588 | Generic | 2026/02/28 | Not stated by source | CDE |
| 浙江诺得药业有限公司 | CYHS2600587 | Generic | 2026/02/28 | Not stated by source | CDE |
| 浙江诺得药业有限公司 | CYHS2504356 | Generic | 2025/12/23 | Not stated by source | CDE |
| 江苏欧歌制药有限公司 | CYHS2602184 | Generic | 2026/09/02 | Not stated by source | CDE |
| 江苏欧歌制药有限公司 | CYHS2602183 | Generic | 2026/09/02 | Not stated by source | CDE |
| AstraZeneca UK Limited;IPR Pharmaceuticals INCORPORATED | JYHB2600475 | Supplement | 2026/08/17 | Not stated by source | CDE |
| AstraZeneca UK Limited;IPR Pharmaceuticals INCORPORATED | JYHB2600474 | Supplement | 2026/08/17 | Not stated by source | CDE |
| AstraZeneca UK Limited;IPR Pharmaceuticals INCORPORATED | JYHB2600473 | Supplement | 2026/08/17 | Not stated by source | CDE |
| 浙江华海制药科技有限公司 | CYHS2601632 | Generic | 2026/07/08 | Not stated by source | CDE |
| 浙江华海制药科技有限公司 | CYHS2601630 | Generic | 2026/07/08 | Not stated by source | CDE |
| 悦康药业集团股份有限公司 | CYHS2600798 | Generic | 2026/04/08 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHS2600498 | Generic | 2026/02/25 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHS2600497 | Generic | 2026/02/25 | Not stated by source | CDE |
| 山西千汇药业有限公司 | CYHS2600124 | Generic | 2026/01/09 | Not stated by source | CDE |
| 四川依科制药有限公司 | CYHS2503808 | Generic | 2025/10/28 | Not stated by source | CDE |
| 四川依科制药有限公司 | CYHS2503807 | Generic | 2025/10/28 | Not stated by source | CDE |
| 山西汾河制药有限公司 | CYHS2503591 | Generic | 2025/10/01 | Not stated by source | CDE |
| 山西汾河制药有限公司 | CYHS2503590 | Generic | 2025/10/01 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 10 filings and 6 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江诺得药业有限公司 | CYHS2600588 | Generic | 2026/02/28 | Not stated by source | CDE |
| 浙江诺得药业有限公司 | CYHS2600587 | Generic | 2026/02/28 | Not stated by source | CDE |
| 江苏欧歌制药有限公司 | CYHS2602184 | Generic | 2026/09/02 | Not stated by source | CDE |
| 江苏欧歌制药有限公司 | CYHS2602183 | Generic | 2026/09/02 | Not stated by source | CDE |
| 浙江华海制药科技有限公司 | CYHS2601632 | Generic | 2026/07/08 | Not stated by source | CDE |
| 浙江华海制药科技有限公司 | CYHS2601630 | Generic | 2026/07/08 | Not stated by source | CDE |
| 悦康药业集团股份有限公司 | CYHS2600798 | Generic | 2026/04/08 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHS2600498 | Generic | 2026/02/25 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHS2600497 | Generic | 2026/02/25 | Not stated by source | CDE |
| 山西千汇药业有限公司 | CYHS2600124 | Generic | 2026/01/09 | Not stated by source | CDE |
API registrations
Non-component matches: 31 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 瑞舒伐他汀钙 | 安徽悦康凯悦制药有限公司 | Y20240001436 | A | Exact ingredient | 2026/07/27 | CDE |
| 瑞舒伐他汀钙 | 江苏普润生物医药有限公司 | Y20240001404 | A | Exact ingredient | 2026/07/27 | CDE |
| 瑞舒伐他汀钙 | M/s. Biocon Limited | Y20240000236 | I | Exact ingredient | 2024/03/21 | CDE |
| 瑞舒伐他汀钙 | Lee Pharma Limited | Y20230000872 | A | Exact ingredient | 2026/03/31 | CDE |
| 瑞舒伐他汀钙 | 浙江江北南海药业有限公司 | Y20230000714 | A | Exact ingredient | 2025/02/14 | CDE |
| 瑞舒伐他汀钙 | 浙江江北药业有限公司 | Y20220000289 | A | Exact ingredient | 2023/09/27 | CDE |
| 瑞舒伐他汀钙 | 浙江永太药业有限公司 | Y20210000962 | A | Exact ingredient | 2023/07/28 | CDE |
| 瑞舒伐他汀钙 | 云鹏医药集团有限公司 | Y20210000652 | A | Exact ingredient | 2024/11/28 | CDE |
| 瑞舒伐他汀钙 | 浙江乐普药业股份有限公司 | Y20210000578 | A | Exact ingredient | 2026/06/16 | CDE |
| 瑞舒伐他汀钙 | 宣城美诺华药业有限公司 | Y20210000329 | A | Exact ingredient | 2022/12/16 | CDE |
| 瑞舒伐他汀钙 | Hanmi Fine Chemical Co., Ltd. | Y20210000135 | A | Exact ingredient | 2024/08/07 | CDE |
| 瑞舒伐他汀钙 | Sun Pharmaceutical Industries Limited | Y20210000168 | A | Exact ingredient | 2024/11/22 | CDE |
| 瑞舒伐他汀钙 | Centrient Pharmaceuticals India Private Limited | Y20210000015 | A | Exact ingredient | 2025/03/15 | CDE |
| 瑞舒伐他汀钙 | 河北广祥制药有限公司 | Y20210000024 | A | Exact ingredient | 2026/10/23 | CDE |
| 瑞舒伐他汀钙 | 南通常佑药业科技有限公司 | Y20200001398 | A | Exact ingredient | 2026/08/08 | CDE |
| 瑞舒伐他汀钙 | 连云港贵科药业有限公司 | Y20200000654 | A | Exact ingredient | 2026/08/18 | CDE |
| 瑞舒伐他汀钙 | 天方药业有限公司 | Y20190000845 | A | Exact ingredient | 2026/07/17 | CDE |
| 瑞舒伐他汀钙 | 湖南九典宏阳制药有限公司 | Y20190021369 | A | Exact ingredient | 2025/11/18 | CDE |
| 瑞舒伐他汀钙 | MSN Laboratories Private Limited | Y20190000940 | A | Exact ingredient | 2025/05/24 | CDE |
| 瑞舒伐他汀钙 | 山东朗诺制药有限公司 | Y20190009618 | A | Exact ingredient | — | CDE |
| 瑞舒伐他汀钙 | 绍兴京新药业有限公司 | Y20190009351 | A | Exact ingredient | 2024/02/08 | CDE |
| 瑞舒伐他汀钙 | 浙江海正药业股份有限公司 | Y20190007514 | A | Exact ingredient | 2023/11/29 | CDE |
| 瑞舒伐他汀钙 | 连云港润众制药有限公司 | Y20190007277 | A | Exact ingredient | — | CDE |
| 瑞舒伐他汀钙 | 山东新时代药业有限公司 | Y20190007037 | A | Exact ingredient | 2022/10/28 | CDE |
| 瑞舒伐他汀钙 | 石药集团欧意药业有限公司 | Y20190007022 | A | Exact ingredient | — | CDE |
| 瑞舒伐他汀钙 | KRKA, d.d., Novo mesto | Y20180001608 | A | Exact ingredient | 2023/08/14 | CDE |
| 瑞舒伐他汀钙 | 先声药业有限公司 | Y20190000761 | A | Exact ingredient | 2025/08/14 | CDE |
| 瑞舒伐他汀钙 | 浙江美诺华药物化学有限公司 | Y20190000565 | A | Exact ingredient | 2026/04/13 | CDE |
| 瑞舒伐他汀钙 | 乳源东阳光药业有限公司 | Y20180001564 | A | Exact ingredient | 2026/04/22 | CDE |
| 瑞舒伐他汀钙 | 绍兴京新药业有限公司 | Y20180000877 | A | Exact ingredient | — | CDE |
| 瑞舒伐他汀钙 | 山东朗诺制药有限公司 | Y20170001976 | A | Exact ingredient | 2024/08/07 | CDE |
| 瑞舒伐他汀钙 | AstraZeneca UK Limited | Y20170001705 | A | Exact ingredient | 2023/08/23 | CDE |
| 瑞舒伐他汀钙 | 浙江江北药业有限公司 | Y20170001629 | A | Exact ingredient | 2024/05/01 | CDE |
| 瑞舒伐他汀钙 | 南京优科制药有限公司 | Y20170001088 | A | Exact ingredient | 2025/12/03 | CDE |
| 瑞舒伐他汀钙 | 常州制药厂有限公司 | Y20170000215 | A | Exact ingredient | 2024/03/14 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/19Supplement delivery
阿斯利康投资（中国）有限公司
JYHB2600323
Fact date: 2026/10/19 · Publication date: 2026/10/20 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 25 ↗ -
2026/10/19Supplement delivery
阿斯利康投资（中国）有限公司
JYHB2600322
Fact date: 2026/10/19 · Publication date: 2026/10/20 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 24 ↗ -
2026/10/19Supplement delivery
阿斯利康投资（中国）有限公司
JYHB2600321
Fact date: 2026/10/19 · Publication date: 2026/10/20 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 23 ↗ -
2026/09/02Accepted
-
2026/09/02Accepted
-
2026/08/17Accepted
AstraZeneca UK Limited;IPR Pharmaceuticals INCORPORATED
JYHB2600475
Fact date: 2026/08/17 · Site observation date: 2026/10/22
View source ↗ -
2026/08/17Accepted
AstraZeneca UK Limited;IPR Pharmaceuticals INCORPORATED
JYHB2600474
Fact date: 2026/08/17 · Site observation date: 2026/10/22
View source ↗ -
2026/08/17Accepted
AstraZeneca UK Limited;IPR Pharmaceuticals INCORPORATED
JYHB2600473
Fact date: 2026/08/17 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy